SCHEMBL30814239

SCHEMBL30814239

CN(C)CCCOCc1nc2c(o1)-c1cc(Cl)ccc1Sc1ccccc1-2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.45
CYP1A2 P05177 5/20 0.45
CYP2D6 P10635 5/20 0.45
CYP2C19 P33261 5/20 0.45
TDP1 Q9NUW8 4/20 0.45
HTR1A P08908 4/20 0.45
DRD2 P14416 4/20 0.45
CYP3A4 P08684 4/20 0.45
CHRM2 P08172 3/20 0.45
ADRA2A P08913 3/20 0.45
ADORA3 P0DMS8 3/20 0.45
CHRM1 P11229 3/20 0.45
DRD1 P21728 3/20 0.45
SLC6A2 P23975 3/20 0.45
SLC6A4 P31645 3/20 0.45
ADRA1A P35348 3/20 0.45
HRH1 P35367 3/20 0.45
OPRM1 P35372 3/20 0.45
DRD3 P35462 3/20 0.45
MC3R P41968 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2293404 1.00 LMNA (0.45) LMNACYP1A2CYP2D6CYP2C19TDP1
SCHEMBL5181405 0.96 LMNA (0.45) LMNACYP1A2CYP2D6CYP2C19TDP1
SCHEMBL5182498 0.94 HTR1A (0.48) LMNACYP1A2CYP2D6CYP2C19TDP1
SCHEMBL5184457 0.90 HTR1A (0.48) LMNACYP1A2CYP2D6CYP2C19TDP1
SCHEMBL5182835 0.90 CYP2D6 (0.38) LMNACYP1A2CYP2D6CYP2C19TDP1
SCHEMBL5181121 0.83 MAPK1 (0.39) HTR1ADRD2CHRM2ADRA2AADORA3
SCHEMBL5182899 0.83 MAPK1 (0.39) CYP1A2CYP2D6HTR1ADRD2CHRM2
SCHEMBL5182945 0.83 BCHE (0.38) LMNACYP1A2CYP2D6CYP2C19TDP1
SCHEMBL2289739 0.81 CYP2D6 (0.37) LMNACYP1A2CYP2D6CYP2C19TDP1
SCHEMBL30814201 0.81 CYP2D6 (0.37) LMNACYP1A2CYP2D6CYP2C19TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4580679-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS Biohaven Therapeutics Ltd. (VG) 2025-07-09 EP disclosed
WO-2024050389-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-07 WO disclosed